


available at www.sciencedirect.com
journal homepage: www.europeanurology.com/eufocus



1 Review – Prostate Cancer

2 Prostate-specific Membrane Antigen Biology in Lethal Prostate 3 Cancer and its Therapeutic Implications

4 **Beshara Sheehan^{a,†}, Christina Guo^{a,b,†}, Antje Neeb^a, Alec Paschalis^{a,b}, Shahneen Sandhu^{c,d},
5 Johann S. de Bono^{a,b,*}**

6 ^aThe Institute of Cancer Research, London, UK; ^bThe Royal Marsden NHS Foundation Trust, London, UK; ^cDepartment of Medical Oncology, Peter MacCallum
7 Cancer Centre, Melbourne, Australia; ^dUniversity of Melbourne, Melbourne, Australia

Article info

Article history:

Accepted June 9, 2021

Associate Editor: Derya Tilki

Keywords:

Prostate-specific membrane antigen
FOLH1
Glutamate carboxypeptidase II
Folate hydrolase
DNA damage repair
Targeted therapies
Biomarker
Prostate cancer
Radionuclide therapy
Theranostic

Abstract

Context: Prostate-specific membrane antigen (PSMA) is a promising, novel theranostic target in advanced prostate cancer (PCa). Multiple PSMA-targeted therapies are currently in clinical development, with some agents showing impressive antitumour activity, although optimal patient selection and therapeutic resistance remain ongoing challenges.

Objective: To review the biology of PSMA and recent advances in PSMA-targeted therapies in PCa, and to discuss potential strategies for patient selection and further therapeutic development.

Evidence acquisition: A comprehensive literature search was performed using PubMed and review of American Society of Clinical Oncology and European Society of Medical Oncology annual meeting abstracts up to April 2021.

Evidence synthesis: PSMA is a largely extracellular protein that is frequently, but heterogeneously, expressed by PCa cells. PSMA expression is associated with disease progression, worse clinical outcomes and the presence of tumour defects in DNA damage repair (DDR). PSMA is also expressed by other cancer cell types and is implicated in glutamate and folate metabolism. It may confer a tumour survival advantage in conditions of cellular stress. PSMA regulation is complex, and recent studies have shed light on interactions with androgen receptor, PI3K/Akt, and DDR signalling. A phase 2 clinical trial has shown that ¹⁷⁷Lu-PSMA-617 causes tumour shrinkage and delays disease progression in a significant subset of patients with metastatic castration-resistant PCa in comparison to second-line chemotherapy. Numerous novel PSMA-targeting immunotherapies, small molecules, and antibody therapies are currently in clinical development, including in earlier stages of PCa, with emerging evidence of antitumour activity. To date, the regulation and function of PSMA in PCa cells remain poorly understood.

Conclusions: There has been rapid recent progress in PSMA-targeted therapies for the management of advanced PCa. Dissection of PSMA biology will help to identify biomarkers for and resistance mechanisms to these therapies and facilitate further therapeutic development to improve PCa patient outcomes.

Patient summary: There have been major advances in the development of therapies targeting a molecule, PSMA, in PCa. Radioactive molecules targeting PSMA can cause tumour shrinkage and delay progression in some patients with lethal disease. Future

[†] These authors contributed equally to this manuscript.

* Corresponding author. The Institute of Cancer Research and Royal Marsden, 15 Cotswold Road, London SM2 5NG, UK. Tel. +44 208 7224029; Fax: +44 208 6427979.

E-mail address: johann.debono@icr.ac.uk (J.S. de Bono).

<https://doi.org/10.1016/j.euf.2021.06.006>

2405–4569/© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: Sheehan B, et al. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. Eur Urol Focus (2021), <https://doi.org/10.1016/j.euf.2021.06.006>

studies are needed to determine which patients are most likely to respond, and how other treatments can be combined with therapies targeting PSMA so that more patients may benefit.

© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

9 **1. Introduction**

10 Prostate-specific membrane antigen (PSMA) is a promising
 11 novel theranostic target in advanced prostate cancer (PCa),
 12 which remains a leading cause of male cancer mortality
 13 [1]. PSMA is overexpressed in PCa cells and is associated
 14 with worse clinical outcomes. Normal tissue expression of
 15 PSMA is restricted to the proximal renal tubules, glial cells,
 16 small intestine, and salivary and lacrimal glands [2–
 17 7]. PSMA has various aliases, including glutamate carboxy-
 18 peptidase II, used primarily in a neurological context, and
 19 folate hydrolase 1 (*FOLH1*), used when describing the gene
 20 encoding PSMA. The physiological role of PSMA in the brain
 21 is to facilitate neuronal glutamate synthesis and its enzymatic
 22 role in the intestine is to facilitate folate absorption.
 23 Its physiological role in prostate cells remains poorly
 24 defined. Given the rapid development of PSMA-targeted
 25 therapies and imaging agents, it is now critical to elucidate
 26 the regulation and function of PSMA in PCa to improve the
 27 precision and maximise the benefits of PSMA-targeted
 28 therapies. This review first focuses on PSMA biology in
 29 PCa, then summarises key clinical studies of PSMA-targeted
 30 therapies in PCa, and finally provides insights into how an
 31 understanding of PSMA biology can inform future therapeutic
 32 strategies to improve patient selection and treatment
 33 outcomes.

34 **2. Evidence acquisition**

35 We performed a review of preclinical and clinical studies
 36 focusing on PSMA-targeted therapies in PCa following the
 37 Preferred Reporting Items for Systematic Reviews and
 38 Meta-Analyses (PRISMA) guidelines. The search was per-
 39 formed on PubMed using the search terms “Prostate Spe-
 40 cific Membrane Antigen”, “Prostate-Specific Membrane
 41 Antigen”, “PSMA”, “*FOLH1*”, “Glutamate Carboxypeptidase
 42 II” or “Folate Hydrolase” in conjunction with “Prostate
 43 Cancer” or “Prostate” in the title or abstract, up to February
 44 2021. Only English language publications were included.
 45 Editorials, guidelines, letters, commentaries, and review
 46 articles were excluded. Conference abstracts of the Ameri-
 47 can Society of Clinical Oncology and European Society of
 48 Medical Oncology up to February 28, 2021 were also
 49 reviewed and included. When there were multiple reports
 50 for the same patient cohort, the most recent and compre-
 51 hensive publication was selected. Studies on refining PSMA
 52 imaging protocols, not directly relevant to PCa treatment or
 53 PSMA targeting therapies, or on agents only being evaluated
 54 in the preclinical setting were excluded.

55 Authors B.S. and C.G. performed article selection and
 56 review independently. Articles were included in the review

after agreement between the authors. Keywords searched
 in study titles and abstracts were used to refine studies for
 initial consideration. The authors then reviewed the full
 texts of studies fitting the inclusion/exclusion requirements
 outlined above. In addition, select articles that provided
 background for PSMA regulation and physiological function
 were included (Fig. 1).

64 **3. Evidence synthesis**

65 **3.1. The PSMA gene (*FOLH1*) and protein**

66 PSMA is encoded by the *FOLH1* gene located on chromo-
 67 some 11p11.12 [8]. Consisting of 19 exons and 18 introns
 68 within a 60-kb region, the gene is under the control of an
 69 upstream promoter and an enhancer region present within
 70 the third intron [9]. It has been shown that SOX-7 (repressor),
 71 the TMPRSS2-ERG gene fusion (repressor), and NFATC-
 72 1 (activator) regulate *FOLH1* gene expression [10–12]. How-
 73 ever, none of these transcription factors are entirely respon-
 74 sible for PSMA expression, suggesting that additional fac-
 75 tors contribute to the regulation of PSMA in PCa.

76 PSMA is a glycosylated, transmembrane carboxypepti-
 77 dase subdivided into three major regions: a short cyto-
 78 plasmic tail, a transmembrane segment, and a large extra-
 79 cellular portion [13]. The role of PSMA depends on the site of
 80 expression. In glial cells, PSMA catalyses the synthesis of
 81 glutamate from the neuropeptide *N*-acetyl-aspartyl-gluta-
 82 mate (NAAG), thereby promoting excitatory neural trans-
 83 mission [13]. In the duodenum, PSMA cleaves glutamate
 84 moieties from dietary polyglutamated folates to produce
 85 monoglutamated folates that are more readily absorbed
 86 [14].

87 **3.2. Regulation of PSMA expression in PCa**

88 **3.2.1. Regulation by the androgen receptor**

89 The dichotomous relationship between PSMA and androgen
 90 receptor (AR) signalling has been described in the preclinical
 91 and clinical settings. Studies using hormone-sensitive
 92 prostate cancer (HSPC) cell lines and xenografts showed
 93 that treatment with testosterone, dihydrotestosterone, or
 94 the synthetic analogue R1881 reduces PSMA expression,
 95 while androgen deprivation therapy (ADT) increased PSMA
 96 expression [15,16].

97 By contrast, a clinical imaging study using ⁶⁸Ga-PSMA
 98 positron emission tomography (PET) showed that ADT
 99 acutely downregulated PSMA expression (maximum [SUV-
 100 max] and mean [SUVmean] standardised uptake values) in
 101 the majority of patients with HSPC who also experienced a
 102 marked decrease in prostate-specific antigen (PSA)




Fig. 1 – PRISMA flow diagram. PCa = prostate cancer; PSMA = prostate-specific membrane antigen.

[17]. Since PSMA expression on PSMA-PET is related to both the number of cells expressing PSMA and target level expression, an initial reduction in PSMA expression on PET imaging in the castration-sensitive setting is likely to be in part attributable to tumour shrinkage in response to ADT as opposed to reduced PSMA expression per cell.

In the castration-resistant setting, enzalutamide or abiraterone led to a marginal increase in PSMA expression on PSMA PET. Notably, this group did not have a significant decrease in PSA [17]. Moreover, a separate study showed that PSMA expression on immunohistochemistry (IHC) was elevated in biopsy tissue from metastatic castration-resistant prostate cancer (mCRPC), which has higher AR signalling [18,19]. The heterogeneity in PSMA expression in advanced mCRPC may also be explained by the fact that AR-negative PCa cell lines and human PCa cells that have transitioned to an AR-negative neuroendocrine/basal phenotype either have significantly reduced or no PSMA expression [19,20].

3.2.2. Regulation by PI3K/Akt/mTOR

PI3K/Akt/mTOR pathway activation occurs in approximately half of advanced PCa. There is significant crosstalk between PI3K/Akt/mTOR and AR signalling [21]. The enzymatic activity of PSMA is probably critical for the crosstalk between PI3K/Akt/mTOR signalling and PSMA [7]. Glutamate, cleaved by PSMA from folates, can drive the PI3K/Akt/mTOR axis by activating G-coupled protein receptors (GPCRs) upstream of the β -isoform of PI3K to perpetuate its signalling (Fig. 2). PSMA expression is also correlated with increased phosphorylation of 4EBP-1, which is modulated by the drug rapamycin, in PCa tumour samples.

Inhibition of downstream targets of the PI3K/Akt/mTOR signalling pathway, such as mTOR1, by rapamycin increases PSMA expression, perhaps as a compensatory mechanism [22].

Rapamycin-sensitive genes significantly associate with “PSMA high” patient samples. This was reiterated by gene set enrichment analysis of PSMA-positive cell lines (LNCaP-Ctrl and PC3-PSMA) and their PSMA-negative counterparts (LNCaP-KD and PC3-Ctrl); genes regulated by Akt and mTOR were significantly linked to PSMA expression. Given the reciprocal feedback between AR and PI3K/Akt signalling, it is likely that modulation of PSMA expression is dependent on the point at which the signalling cascades are targeted and the *PTEN* status of the cells. Overall, these studies indicate that modulation of the PI3K/Akt pathway should be explored as a strategy to upregulate PSMA expression.

3.2.3. Regulation by DNA damage

PSMA may regulate glutamate and folate availability to cells. These molecules are fundamental to nucleotide synthesis, a process upregulated in cells requiring DNA damage repair (DDR). Both the PI3K/Akt/mTOR and AR signalling axes can regulate DDR pathways, and it has been reported that their blockade sensitises to DNA-damaging agents [23,24]. Mechanistically, PI3K inhibitors reduce nucleoside pools, which can induce replication stress, and AR inhibition reduces receptor mediation of DDR with co-regulators [24,25]. This hypothesis is further underscored by the observation that DDR-defective mCRPCs have higher PSMA expression than those without DDR defects [19]. Another study showed that *BRCA2* knockout in PCa cell lines results in an increase in PSMA expression [26]. Interestingly, PCa




Fig. 2 – Schematic of cellular function of PSMA in PCa cells based on established in vitro studies. PSMA enzymatic function cleaves glutamate from poly-G-folates, NAAG, laminin peptides, and other unknown glutamated substrates. The liberation of glutamate and its subsequent binding to glutamate receptors (GPCRs) results in upregulation of the oncogenic PI3K(110β subunit)/Akt/mTOR signalling pathway. Synthesis of NAAG by recurrent ovarian and pancreatic tumour cells generates a local glutamate reservoir only accessed by PSMA expression. Mono-G-folate generation from PSMA enzymatic action on poly-G-folate increases locally available folate and therefore uptake by the RFC and other means in PCa cells. This is particularly relevant in low folate conditions, in which pathways to increase folate uptake are essential for normal folate homeostasis. Concurrent liberation of glutamate from various substrates by PSMA contributes to energy generation by cancer cells, feeding into the TCA cycle. Enzymatic action on previously MMP-degraded laminin peptides generates both glutamate and angiogenic peptides. This glutamate conceivably activates GPCRs to activate PI3K(110β) or is utilised metabolically within the cell.
 PSMA = prostate-specific membrane antigen; PIP2 = phosphatidylinositol-(4,5)-bisphosphate; PIP3 = phosphatidylinositol-(3,4,5)-trisphosphate; PI3K = phosphoinositide 3-kinase; RFC = reduced folate carrier; Akt = protein kinase B; TCA = tricarboxylic acid cycle; GPCR = G-coupled protein receptor; MMP = matrix metalloproteinase.

with TP53 loss exhibited resistance to PSMA-targeted β-particle therapy *in vivo* [27] and to α-particle therapy in patients with CRPC [28]. This is somewhat counterintuitive, as a defective DDR response would presumably sensitise a cell to a DNA-damaging agent, as it cannot recover its genomic integrity correctly. This may be down to which genes in the various DDR cascades are defective. Genomic defects coding for proteins that inhibit cell cycle progression, such as CDC25A, can lead to radioresistant DNA synthesis [29]. Therefore, the cell can still repair its DNA but it cannot stop cell cycle progression, even when there is irreparable DNA damage. Mutations in central DDR mediators, such as BRCA2, often sensitise to radiation [30] as the DDR mechanism is comparatively limited. In either situation, cells are likely to be in a state of stress due to uncontrolled proliferation or continually increasing DNA damage, with the significant metabolic requirements of these scenarios. Therefore, PSMA expression is likely to be expressed because of cell stress; however, high PSMA expression may not necessarily indicate resistance to DNA-damaging agents. In order to substantiate these relationships, changes in PSMA expression as a direct consequence of cell stress, including the specific DDR defects noted in PSMA-positive CRPC, should be investigated.

3.3. Function of PSMA in PCa

PSMA has been implicated in folate and glutamate mobilisation, uptake, and signalling (Fig. 2). Both glutamate and folate are involved in wide-ranging cellular processes, including DDR, bioenergetics, protein synthesis, and cellular signalling. Interestingly, it has been reported that PSMA is involved in folate transport in PCa cells and converts locally synthesised NAAG to N-acetyl aspartate and glutamate [31]. PSMA overexpression in PCa cells confers a survival advantage over non-PSMA-expressing cells in folate-depleted conditions [32]. PCa cells are likely to be highly sensitive to folate deprivation because of their greater demand for folate for polyamine synthesis [33]. PSMA generates monoglutamated folates, which can pass across the cell membrane, from polyglutamated folates [31,32]. The uptake of folic acid, a synthetic form of dietary folate, is higher in PSMA-positive cells [33]. Furthermore, metabolic scores comprising genes associated with folate metabolism, the one-carbon cycle, and polyamine synthesis are considerably higher in a cohort of localised prostate cancers (TCGA-PRAD), compared to other tumour types, suggesting that PCa cells have higher demand for the products of folate metabolism [34]. PSMA is probably critical in this process.

It has also been reported that glutamine is an alternative energy source in PCa cells through glutaminolysis. During glutaminolysis, glutamine is broken down into glutamate and ammonia as products of the first step; the former is used as a substrate for the tricarboxylic cycle [35,36]. PSMA is implicated in the generation of glutamate via its enzymatic action on glutamate moieties of NAAG, polyglutamated folates, and laminin peptides in the extracellular matrix [32,37,38]. PSMA is required for liberation of glutamate from tumour-derived NAAG, although this relationship has not yet been investigated in the context of PCa [37]. It has been shown that PSMA generates a localised reservoir of glutamate from NAAG and fuels tumour growth in high-grade ovarian serous adenocarcinoma cells [37]. Matrix metallopeptidases, which are also upregulated in PCa [39,40], break down laminin peptides to generate peptide components with glutamate moieties. PSMA can then act on these to generate proangiogenic peptides and glutamate [38,41]. Other enzymes involved in glutaminolysis, a process that converts glutamate into substrate for the tricarboxylic acid cycle, are upregulated in PCa [42]. Furthermore, it has been shown that patients with high-risk PCa have high serum glutamate levels [43]. While the role of PSMA in glutaminolysis in PCa is not fully understood, it is possible that increasing cellular stress and metabolic demand for glutamate could increase PCa cell vulnerability to PSMA targeting.

3.4. PSMA as a therapeutic target and biomarker in PCa

Given the high expression of PSMA by PCa cells and its biological functions, targeting of PSMA has been the focus of intense clinical research in PCa. Numerous PSMA-targeting agents, including radionuclide therapy (RLT; with an antibody or small molecule), PSMA-targeting immunotherapies (bi- and tri-specific T-cell engagers), and antibody-drug conjugates (ADCs) are currently in clinical development. Many of these agents have demonstrated promising antitumour activity, with a ¹⁷⁷Lutetium (¹⁷⁷Lu) conjugated small-molecule peptide (¹⁷⁷Lu-PSMA-617) the furthest in clinical development (NCT03511664; Table 1 [44-46,51]).

3.4.1. PSMA-directed radiopharmaceuticals

PSMA-targeting radiopharmaceuticals can be labelled with different radionuclides for diagnostic (eg, positron emitter gallium-68) or therapeutic (eg, the β -particle emitter ¹⁷⁷Lu and the α -particle emitters Actinium-225 [²²⁵Ac] and Thorium-227 [²²⁷Th]) purposes. Changes to the radionuclide linker, chelator, and PSMA binding domains can alter the pharmacokinetic and pharmacodynamic properties, and consequently impact the antitumour activity and toxicity profile. α -particles have higher linear energy transfer but a shorter range than β -particles; the result is more DNA damage to nearby cells but less penetration into surrounding tissue. Thus, α and β emitters are likely have different advantages depending on the disease pattern [47,48].

3.4.2. β -emitting RLTs

PSMA ligands such as PSMA-617, MIP-1095, and PSMA-I&T (“imaging and therapy”) can be labelled with β -emitters such as ¹⁷⁷Lu or Iodine-131 (¹³¹I) for RLT. A nonrandomised phase 2 study of ¹⁷⁷Lu-PSMA-617 (up to 6 cycles, 6 wk apart) in 50 patients who had experienced progression after taxane chemotherapy and second-generation novel antiandrogens, selected on the basis of high PSMA avidity and the absence of discordant PSMA-negative metastases on fluorodeoxyglucose (FDG) PET imaging, reported that 64% of patients achieved the primary endpoint of a PSA decline of $\geq 50\%$. This was subsequently shown to be associated with longer overall survival. Of the 27 patients who had measurable soft-tissue disease, 15 (56%) had a partial radiological response [45,49]. Notably, 11/15 (73%) patients who had previously responded to ¹⁷⁷Lu-PSMA-617 and were retreated with ¹⁷⁷Lu-PSMA-617 achieved a PSA decline of $\geq 50\%$ with retreatment. The most common treatment-emergent adverse effects were self-limiting xerostomia (all grade 1–2; 66%), transient nausea (all grade 1–2; 48%), thrombocytopenia (grade 3–4; 10%), and anaemia (grade 3; 10%) [45,49]. This treatment was subsequently evaluated in a randomised phase 2 study comparing ¹⁷⁷Lu-PSMA-617 with cabazitaxel in patients selected using the same imaging criteria. Eighty of the 291 participants registered were excluded on the basis of imaging criteria. Patients receiving ¹⁷⁷Lu-PSMA-617 had significantly higher rates of PSA response (decrease by $\geq 50\%$: 66% vs 33%) and radiological response (49% vs 24%), and longer progression-free survival. The most common treatment-emergent adverse effects were fatigue and cytopenias, although treatment was well tolerated when compared with cabazitaxel [50]. The phase 3 VISION trial randomised mCRPC patients (2:1) who had progressed after at least one line of novel androgen axis-targeted therapy and at least one taxane regimen with PSMA-positive metastatic disease and no moderately-sized PSMA-negative metastatic disease to ¹⁷⁷Lu-PSMA-617 or best supportive care. This trial had a high screen positive rate of 87%. The trial initially suffered from a high dropout rate partly because radium-223 and chemotherapy were not permitted in the control arm. Dropout improved with mitigation measures including site education. The study met its primary and secondary endpoints with the ¹⁷⁷Lu-PSMA-617 arm demonstrating a significant improvement in overall survival, radiologic progression-free survival, PSA and RECIST response. These results will likely see ¹⁷⁷Lu-PSMA-617 become a part of the prostate cancer treatment armamentarium to be sequenced after AR-targeted agents and chemotherapy [51].

A ¹⁷⁷Lu-labelled diagnostic or therapeutic PSMA ligand (DOTAGA-[I-y]fk[Sub-KuE], also called PSMA-I&T) is being prospectively evaluated. In a series of 56 patients with progressive mCRPC for whom PSMA uptake was determined via ⁶⁸Ga-PSMA, 59% achieved a PSA decline of $>50\%$ after receiving ¹⁷⁷Lu-PSMA-I&T. Objective, partial radiological response was observed in 20% of the 25 patients with measurable disease. There was no clinically significant haematological toxicity, nephrotoxicity, or xerostomia. Similar to studies of ¹⁷⁷Lu-PSMA-617, the most common adverse

265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323

Table 1 – Key clinical studies of PSMA-directed therapies in clinical development

Class	Agent	Setting	Phase	Clinical trial registration	Publication	
β-Emitting small molecule	Monotherapy					
	¹⁷⁷ Lu-PSMA-617	High-risk localised or locoregional APC (neoadjuvant)	Phase 1/2	NCT04430192		
	¹⁷⁷ Lu-PSMA-617	mCRPC	Phase 2	ACTRN12615000912583 ^a	Published [45,49]	
	¹⁷⁷ Lu-PSMA-617 vs cabazitaxel	mCRPC	Phase 2	NCT03392428	Published [50]	
	¹⁷⁷ Lu-PSMA-617 vs best supportive/standard of care	mCRPC	Phase 3	NCT03511664	Published [99] ^b	
	¹⁷⁷ Lu-PSMA-617 (fractionated dosing)	mCRPC	Phase 1	NCT03042468		
	¹⁷⁷ Lu-PSMA-I&T	Oligometastatic HSPC	Phase 2	NCT04443062		
	¹⁷⁷ Lu-PSMA-617 vs AR-targeted therapy	mCRPC	Phase 3	NCT04689828		
	¹⁷⁷ Lu-PSMA-I&T	Neoadjuvant for localised APC	N/A	NCT04297410		
	¹⁷⁷ Lu-PSMA-I&T vs abiraterone or enzalutamide	mCRPC	Phase 3	NCT04647526		
	Combinations					
	¹⁷⁷ Lu-J591 and ¹⁷⁷ Lu-PSMA-617	mCRPC	Phase 1/2	NCT03545165		
	¹⁷⁷ Lu-PSMA-617 and pembrolizumab	mCRPC	Phase 1	NCT03805594		
	¹⁷⁷ Lu-PSMA-617 followed by docetaxel vs docetaxel	Metastatic HNPC	Phase 1/2	NCT03658447		
	¹⁷⁷ Lu-PSMA-617 plus olaparib	mCRPC	Phase 2	NCT04343885		
¹⁷⁷ Lu-PSMA-617 plus olaparib	mCRPC	Phase 1	NCT03874884			
¹⁷⁷ Lu-PSMA-617 plus enzalutamide	mCRPC	Phase 2	NCT04419402			
β-Emitting antibodies	Monotherapy					
	⁹⁰ Y- or ¹⁷⁷ Lu-J591 mAbs	CRPC	Phase 1	N/A	Published [58,59]	
	⁹⁰ Y-J591	CRPC	Phase 1	N/A	Published [54]	
	¹⁷⁷ Lu-J591	CRPC	Phase 1	N/A	Published [55]	
	¹⁷⁷ Lu-J591	mCRPC	Phase 2	NCT00195039	Published [56]	
	¹⁷⁷ Lu-J591 (fractionated dosing schedule)	mCRPC	Phase 1	NCT00538668	Published [57,97]	
	Combinations					
	Docetaxel/prednisone plus ¹⁷⁷ Lu-J591 Ab (fractionated)	mCRPC	Phase 1	NCT00916123	Published [88]	
	¹⁷⁷ Lu-J591 plus KCZ and HC vs ¹¹¹ In-J591 (Ab without radioactive particle) plus KCZ and HC	Micrometastatic CRPC	Phase 2	NCT00859781		
	α-Emitting antibody	²²⁵ Ac-J591	mCRPC	Phase 1	NCT03276572	Published [61]
		Thorium-227 conjugate PSMA (BAY 2315497)	mCRPC	Phase 1	NCT03724747	
		PSMA/CD3BiTE/TriTAC	AMG160 monotherapy and combination with pembrolizumab	mCRPC	Phase 1	NCT03792841
	PSMA ADC	Pasotuximab (BAY2010112)	mCRPC	Phase 1	NCT01723475	Published [68,72]
		HPN424	mCRPC	Phase 1/2	NCT03577028	Published [69,98] ^b
		PSMA ADC (IgG1 Ab with monomethyl auristatin E)	mCRPC	Phase 1	NCT01414283	Published [73]
PSMA ADC	PSMA ADC (IgG1 Ab with monomethyl auristatin E)	mCRPC (post taxane)	Phase 2	NCT01695044	Published [75] ^b	
	PSMA ADC (IgG1 Ab with monomethyl auristatin E)	mCRPC (post abiraterone/ and/or enzalutamide)	Phase 2	NCT02020135	Published [74] ^b	

Ab = antibody; ADC = antibody-drug conjugate; APC = advanced prostate cancer; AR = androgen receptor; BiTE = bispecific T-cell engager; CRPC = castration-resistant prostate cancer; HNPC = hormone-naïve prostate cancer; HSPC = hormone-sensitive prostate cancer; mAb = monoclonal Ab; mCRPC = metastatic CRPC; HC = hydrocortisone; KCZ = ketoconazole; N/A = not applicable; PSMA = prostate-specific membrane antigen; TriTAC = trispecific T-cell engager.

^a Australian New Zealand Clinical Trials Registry.

^b Publication in abstract form at the literature review cutoff date.

324 events were grade 1–2 anaemia, leukopenia, and transient
 325 xerostomia, although thrombocytopenia was not reported
 326 [52]. Several studies are also evaluating whether ¹⁷⁷Lu-
 327 PSMA-617 and ¹⁷⁷Lu-PSMA-I&T would be beneficial in ear-
 328 lier stages of disease (NCT04343885, NCT04443062,
 329 NCT04297410, NCT03828838, and NCT04430192) (Table 1).

3.4.3. PSMA-targeting antibodies

330 Apart from conjugated small molecules, PSMA-targeting
 331 antibodies conjugated with a β-emitter are also in clinical
 332 development. The anti-PSMA monoclonal antibody J591 has
 333 been conjugated with Yttrium-90 (⁹⁰Y) and ¹⁷⁷Lu using
 334 dodecane tetraacetic acid as the chelate. The unarmed
 335

antibody had minimal antitumour activity [53]. Antitumour activity was first demonstrated in a phase 1 trial of ⁹⁰Y-J591 in which partial radiological responses and a PSA decline of >50% occurred in two patients [54]. Subsequently, ¹⁷⁷Lu-J591 has been evaluated in five published phase 1/2 clinical trials in patients with mCRPC without imaging selection. These studies demonstrated dose-dependent antitumour activity. The phase 1 study established a recommended phase 2 dose (RP2D) of 70 mCi/m² [55,56]. The most common side effects were cytopenias, which were mostly reversible [55–59]. Given the larger size of the antibody compared to small-molecule inhibitors of PSMA, ¹⁷⁷Lu-J591 has a longer circulating time. ¹⁷⁷Lu-J591 also has less exposure at the renal tubules and small intestinal brush border than small-molecule RLTs, so has a different side-effect profile; it causes more haematological toxicities, but potentially has less impact on the kidneys, salivary glands, and small intestine [55,56].

In light of dose-limiting myelotoxicity in the phase 1 study, a phase 1/2 study evaluated the effect of fractionation (20–45 mCi/m², 2 doses, 2 wk apart). It showed that this approach improved the therapeutic window by decreasing the radioactivity per dose to the bone marrow and increasing the total tumour dose [57]. At the highest RP2D (45 mCi/m², 2 doses), 29% of patients had a PSA decline of >50%; 35% had reversible grade 4 neutropenia and 59% had thrombocytopenia [57]. A subsequent pilot study evaluating hyperfractionation (25 mCi/m² every 2 wk until grade 2 toxicity), with the intention that this may allow the delivery of even higher cumulative doses, did not demonstrate an additional benefit. Further studies using the two-dose fractionation schedule are planned [60]. An important question remains as to how PSMA-targeting small molecules compare to antibodies in terms of antitumour activity and overall safety.

3.4.4. *α*-emitting RLTs

Several *α*-emitting PSMA-targeting RLTs are in clinical development, including the antibody-based RLT ²²⁵Ac-J591 (NCT03276572), a PSMA-targeted ²²⁷Th conjugate (PSMA-TTC; BAY 2315497; NCT03724747), and the small-molecule conjugates ²²⁵Ac-PSMA-I&T and ²²⁵Ac-PSMA-617 (NCT04597411) [61–63]. The antitumour activity of ²²⁵Ac-PSMA-617 and ²²⁵Ac-PSMA-I&T in mCRPC patients has been reported in retrospective case series, including in some patients who had previously experienced progression on a *β*-emitting PSMA-targeting RLT [63–65]. However, xerostomia led to weight loss and treatment discontinuation in some cases [64]. Efforts to mitigate *α*-emitter-induced glandular damage include conjugation with an antibody to reduce salivary gland distribution, fractionation, dose titration, and salivary gland protective measures [65], although their effectiveness remains unclear. To date, there has been no head-to-head comparison of *α*- and *β*-emitting PSMA-targeting RLTs.

3.4.5. PSMA-targeting immunotherapies

PSMA-directed bispecific T-cell engagers (BiTEs) consisting of an antibody targeting both PSMA and the CD3 T-cell

receptor to induce T-cell activation, PCa-directed cell lysis, and growth inhibition have shown antitumour activity both in vitro and in vivo [66,67]. Several agents (AMG160, pasotuzumab/AMG212/BAY2010112) are in clinical development as monotherapy (NCT03792841) or in combination with an anti-PD-1 antibody (NCT01723475). Pasotuzumab demonstrated early evidence of clinical activity with partial response seen in a patient who had previously failed to respond to ¹⁷⁷Lu-PSMA-617, although administration is via continuous intravenous infusion [68]. Another PSMA-directed BiTE, AMG160, is currently being evaluated in a phase 1 dose-escalation study in patients with heavily pretreated mCRPC. According to a preliminary report, 6/10 patients had a PSA (>50%) response and one had a confirmed partial response among patients treated at the two highest dose levels. This included patients who had previously received PSMA-targeted RLT. Predictable and generally low-grade cytokine release syndrome was easily mitigated by dexamethasone premedication, prehydration, and a lower run-in dose. A trispecific T-cell-activating construct consisting of a PSMA-targeting domain, a CD3-targeting domain, and a third domain that binds noncovalently to serum albumin to extend the half-life (HPN424) is also in phase 1 clinical development (NCT03577028) [69]. While *in vitro* studies of AMG160 indicated that PSMA expression is necessary for antitumour activity [70], the clinical trial did not select patients on the basis of PSMA expression [71,72]. Since PSMA-targeting T-cell-activating therapies rely on indirect tumour lysis by T cells, which can potentially impact adjacent non-PSMA-positive tumour cells, it is plausible that heterogeneous or lower levels of expression are sufficient to confer antitumour immunity [67,70]. Biomarker studies from these clinical trials will further elucidate the biology of PSMA-directed T-cell-activating therapies.

3.4.6. PSMA-directed therapies with nonspecific cytotoxic agents

The high expression of PSMA in a significant subset of PCa makes it an ideal target for delivery of a nonspecific cytotoxic payload using an ADC. A fully humanised antibody to PSMA linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) was evaluated in a phase 1 dose-escalation study in which 52 patients with mCRPC who had experienced progression on taxanes were treated at doses ranging from 0.4 to 2.8 mg/kg. Neutropenia and peripheral neuropathy were early and late dose-limiting toxicities, respectively, which established the maximum tolerated dose of 2.5 mg/kg. A PSA decline of ≥50% was observed in 8/40 patients (20%) who received doses of ≥1.8 mg/kg [73]. Preliminary results from two phase 2 studies of this PSMA-targeting ADC, which included both taxane-refractory and chemotherapy-naïve mCRPC cases, demonstrated antitumour activity at both the 2.5 mg/kg and 2.3 mg/kg doses. Dosing was initiated at 2.5 mg/kg and adjusted to 2.3 mg/kg because of neutropenia [74,75]. Previous efforts to develop PSMA-targeting ADCs have been less successful. The development of MLN2704, a PSMA-targeting monoclonal antibody linked to the anti-microtubule chemotherapy agent maytansinoid, was terminated

because of linker lability leading to payload deconjugation and peripheral neuropathy [76,77]. While promising, these approaches are also limited by the heterogeneity of PSMA expression, highlighting the need to elucidate the biology of PSMA regulation and expression. Therefore, combinatory treatments that enhance PSMA expression on PCa cells will arguably benefit this subset of therapies the most.

3.5. Biomarker development for PSMA-targeting

Given the rapid advances in and success of PSMA-targeting RLT, there is now an urgent need to optimise patient selection for these treatments. Prospective studies of ¹⁷⁷Lu-PSMA-617 in patients often select according to the presence of tumour PSMA expression, defined as SUV_{max} for tumour involvement of at least 1.5 times the SUV_{mean} for liver, and the lack of major discordant FDG-positive and PSMA-negative disease [49,78], although it remains unclear what the lower threshold of expression for benefit is. Studies of other α- and β-emitting PSMA-targeted RLTs published to date have not selected patients on the basis of PSMA expression and are underpowered for biomarker analyses.

Inpatient heterogeneity and the dynamic nature of PSMA expression present additional challenges for biomarker development [19,79]. Various methods to enhance tumour visualisation by reducing physiological or background uptake are under investigation. These include pre-imaging supplementation with monosodium glutamate or the “cold” radioconjugate; however, monosodium glutamate did not improve tumour visualisation [80,81]. PET imaging offers advantages over IHC in characterising heterogeneous PSMA expression across different metastatic sites and mapping longitudinal changes in PSMA expression, while IHC assays elucidate heterogeneity in PSMA expression at a cellular level. A study of primary PCa biopsies that were PSMA-negative on IHC predicted for the lack of avidity on PSMA-PET. It is unclear, however, whether patients with PSMA-PET-negative disease, for whom low-level or heterogeneous expression on IHC is observed, may still benefit from PSMA-targeted therapy through bystander and/or crossfire effect [82]. Nevertheless, PSMA IHC expression in diagnostic tumour biopsy samples is unlikely to be representative of expression at metastatic sites and in advanced later-stage disease [15,83–85]. As discussed earlier, standard-of-care PCa treatments alter PSMA expression, and expression generally increases with disease progression. Overall, fresh tumour biopsies for IHC analyses and PET imaging are likely to be complementary. Prospective studies incorporating serial and orthogonal measures of PSMA expression, as well as other biomarkers measuring vulnerability to radiotherapy or payload chemotherapy, are needed to identify potential responders.

3.6. Overcoming resistance

It has now been shown that PSMA-targeted RLT benefits a significant subset of patients with mCRPC, with additional studies evaluating its efficacy in earlier stages of disease. Further studies are now needed to broaden the benefit of

these treatments and to develop strategies to overcome secondary resistance. Measures to improve the therapeutic window through dose fractionation, enhanced drug delivery, and retention are being pursued. Other strategies to overcome primary and secondary resistance to RLT include combining existing agents with drugs that upregulate PSMA expression, synergise with the cytotoxic agents or radiation, or target pathways, such as PI3K/Akt/mTOR, that have cross-talk with PSMA [86,87]. In addition, PSMA-independent pathways may play a role in resistance to PSMA-targeted therapies, so unbiased analyses of pre- and post-treatment samples are critical in these studies. Strategies that increase the dependence of PCa cells on PSMA for survival (e.g. by altering glutaminolysis) also merit further study.

Given that PSMA is involved in generating folate and glutamate, with expression associated with defective DDR, PSMA-targeting radionuclides may also synergise with treatments that cause further DNA damage or inhibit the DDR response [19]. Radiation and chemotherapy both cause DNA damage. When combined with inhibition of PSMA function, this approach may be synergistic. Moreover, DNA-damaging agents and DDR inhibitors increase replication stress, which in turn could upregulate PSMA [19]. This may be of particular relevance to patients with tumours harbouring defective DNA repair genes. Chemotherapies such as taxanes can also reduce tumour bulk and radiosensitise cells. The feasibility of this approach was studied in a phase 1 trial of the combination of dose-fractionated ¹⁷⁷Lu-J591 (2 doses, 2 wk apart, up to a planned dose of 2.96 GBq/m²) and docetaxel in patients with mCRPC. As expected, haematological toxicities were common but reversible. Antitumour activity, as shown by a >50% PSA decline in 11/15 patients (73%) and a partial radiological response in 3/5 patients (60%) with measurable disease, was observed [88]. Given the aforementioned interaction between AR and PSMA [85,89,90], combining AR blockade and PSMA targeting may also improve their efficacy.

Radiotherapy may synergise with immunotherapy through abscopal effects, which occurs, in part, because of induction of systemic antitumour immunity [91,92]. Radiation induces genomic instability, neoantigen formation, and activation of both innate and adaptive immune responses that promote immune surveillance. Simultaneous upregulation of immune checkpoints, however, may limit this [93–95]. Thus, immunotherapy could enhance systemic antitumour immunity while specifically targeting compensatory immune evasive adaptations. A preclinical study indicated that the combination of ²²⁵Ac-PSMA-617 and anti-PD-1 delayed tumour progression in immunocompetent syngeneic mouse tumour models [96]. Early-phase clinical trials combining PSMA-targeting radionuclides or PSMA-targeting radionuclides with AR blockade, PARP inhibitors, chemotherapy, and immunotherapy are ongoing (Table 1).

4. Conclusions

In conclusion, PSMA-targeting therapies have demonstrated impressive antitumour activity and clinical benefit

562 in recent clinical studies. Orthogonal and serial characteri-
 563 sation of PSMA expression during these studies is now
 564 urgently needed to define the optimal biomarker selection
 565 strategies for PSMA-targeted therapies. Since PSMA expres-
 566 sion is heterogeneous and dynamic, its regulation needs
 567 better elucidation to drive rational drug development
 568 efforts aimed at modulating PSMA expression to improve
 569 efficacy. Understanding the biological functions of PSMA
 570 will also help to identify cellular vulnerabilities to these
 571 therapies, leading to therapeutic combinations that over-
 572 come treatment resistance and maximise clinical benefit.

573 **Author contributions:** Johann S. de Bono had full access to all the data in
 574 the study and takes responsibility for the integrity of the data and the
 575 accuracy of the data analysis.

576 *Study concept and design:* de Bono, Sheehan, Guo.
 577 *Acquisition of data:* Guo, Sheehan.
 578 *Analysis and interpretation of data:* Sheehan, Guo.
 579 *Drafting of the manuscript:* Guo, Sheehan.
 580 *Critical revision of the manuscript for important intellectual content:* de
 581 Bono, Guo, Sheehan, Sandhu, Paschalis, Neeb.
 582 *Statistical analysis:* None.
 583 *Obtaining funding:* de Bono.
 584 *Administrative, technical, or material support:* None.
 585 *Supervision:* de Bono.
 586 *Other:* None.

587 **Financial disclosures:** Johann S. de Bono certifies that all conflicts of
 588 interest, including specific financial interests and relationships and
 589 affiliations relevant to the subject matter or materials discussed in the
 590 manuscript (eg, employment/affiliation, grants or funding, consultan-
 591 cies, honoraria, stock ownership or options, expert testimony, royalties,
 592 or patents filed, received, or pending), are the following: Beshara Shee-
 593 han, Christina Guo, Antje Neeb, Alec Paschalis, and Johann S. de Bono are
 594 employees of The Institute of Cancer Research (ICR), which has a com-
 595 mercial interest in abiraterone. The ICR operates a Rewards to Inventors
 596 scheme through which employees may receive financial benefit follow-
 597 ing commercial licensing. Johann S. de Bono has served on advisory
 598 boards and received fees from many companies, including AstraZeneca,
 599 Astellas, Bayer, Bioexcel Therapeutics, Boehringer Ingelheim, Cellcentric,
 600 Daiichi, Eisai, Genentech/Roche, Genmab, GSK, Janssen, Merck Serono,
 601 Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qia-
 602 gen, Sanofi Aventis, Sierra Oncology, Taiho, and Vertex Pharmaceuticals.
 603 His ICR research has received funding or other support from AstraZeneca,
 604 Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen,
 605 Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Sanofi Aventis,
 606 Sierra Oncology, Taiho, Pfizer, and Vertex, and the ICR has a commercial
 607 interest in abiraterone, PARP inhibition in DNA repair defective cancers,
 608 and PI3K/AKT pathway inhibitors (no personal income). He was named
 609 as an inventor, with no financial interest, for patent 8 822 438. He has
 610 been the chief investigator/principal investigator for many industry-
 611 sponsored clinical trials. Shahneen Sandhu is an employee of the Peter
 612 MacCallum Cancer Centre, which has received funding or other support
 613 for research work from AstraZeneca, Novartis, Amgen, Pfizer, Genentech,
 614 Merck Sharp & Dohme, and Merck Serono. She has received honoraria
 615 donated to her institution from Merck Sharp & Dohme, AstraZeneca, and
 Bristol-Myers Squibb.

616 **Funding/Support and role of the sponsor:** Johann S. de Bono gratefully
 617 acknowledges research funding from Prostate Cancer UK, the Movember

Foundation through the London Movember Centre of Excellence 618
 (CEO13_2-002), the Prostate Cancer Foundation, the US Department of 619
 Defense Cancer Research UK, Cancer Research UK (Centre Programme 620
 grant), Experimental Cancer Medicine Centre grant funding from Cancer 621
 Research UK and the Department of Health, and Biomedical Research 622
 Centre funding to the Royal Marsden (ECMC CRM064X). Johann S. de 623
 Bono is a National Institute for Health Research (NIHR) Senior Investigator. 624
 Christina Guo gratefully acknowledges research funding from the 625
 Wellcome Trust, US Department of Defense, and Prostate Cancer 626
 Foundation. The views expressed in this article are those of the 627
 author(s) and not necessarily those of the aforementioned funders, 628
 NHS, the NIHR, or the Department of Health. 629

630 **References**

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global 631
 cancer statistics 2018: GLOBOCAN estimates of incidence and mortality 632
 worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 633
 2018;68:394–424.

[2] Sartor O, de Bono JS. Metastatic prostate cancer. *N Engl J Med* 634
 2018;378:645–57.

[3] Lawal IO, Bruchertseifer F, Vorster M, Morgenstern A, Sathekge MM. 635
 Prostate-specific membrane antigen-targeted endoradiotherapy in 636
 metastatic prostate cancer. *Curr Opin Urol* 2020;30:98–105.

[4] Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate- 637
 specific membrane antigen in normal and malignant human tissues. 638
World J Surg 2006;30:628–36.

[5] Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate- 639
 specific membrane antigen expression in normal and malignant 640
 human tissues. *Clin Cancer Res* 1997;3:81–5.

[6] Wright Jr GL, Haley C, Beckett ML, Schellhammer PF. Expression of 641
 prostate-specific membrane antigen in normal, benign, and malig- 642
 nant prostate tissues. *Urol Oncol* 1995;1:18–28.

[7] Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific 643
 membrane antigen cleavage of vitamin B9 stimulates oncogenic 644
 signaling through metabotropic glutamate receptors. *J Exp Med* 645
 2018;215:159–75.

[8] O’Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization 646
 and promoter analysis of the human prostate-specific membrane 647
 antigen gene. *Biochim Biophys Acta* 1998;1443:113–27.

[9] Watt F, Martorana A, Brookes DE, et al. A tissue-specific enhancer of 648
 the prostate-specific membrane antigen gene, FOLH1. *Genomics* 649
 2001;73:243–54.

[10] Peng W, Guo L, Tang R, et al. Sox7 negatively regulates prostate- 650
 specific membrane antigen (PSMA) expression through PSMA- 651
 enhancer. *Prostate* 2018;79:370–8.

[11] Lee SJ, Lee K, Yang X, et al. NFATc1 with AP-3 site binding specificity 652
 mediates gene expression of prostate-specific-membrane-antigen. *J* 653
Mol Biol 2003;330:749–60.

[12] Yin L, Rao P, Elson P, Wang J, Ittmann M, Heston WD. Role of 654
 TMPRSS2-ERG gene fusion in negative regulation of PSMA expres- 655
 sion. *PLoS One* 2011;6:e21319.

[13] Mesters JR, Barinka C, Li W, et al. Structure of glutamate carboxy- 656
 peptidase II, a drug target in neuronal damage and prostate cancer. 657
EMBO J 2006;25:1375–84.

[14] Halsted CH. Jejunal brush-border folate hydrolase. A novel enzyme. 658
West J Med 1991;155:605–9.

[15] Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive mea- 659
 surement of androgen receptor signaling with a positron-emitting 660
 radiopharmaceutical that targets prostate-specific membrane anti- 661
 gen. *Proc Natl Acad Sci U S A* 2011;108:9578–82.

[16] Meller B, Bremmer F, Sahlmann CO, et al. Alterations in androgen 662
 deprivation enhanced prostate-specific membrane antigen (PSMA) 663
 664
 665

- expression in prostate cancer cells as a target for diagnostics and therapy. *EJNMMI Res* 2015;5:66.
- [17] Emmett L, Yin C, Crumbaker M, et al. Rapid modulation of PSMA expression by androgen deprivation: serial ^{68}Ga -PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. *J Nucl Med* 2019;60:950–4.
- [18] Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. *Cell* 2015;162:454.
- [19] Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. *Eur Urol* 2019;76:469–78.
- [20] Bakht MK, Derecichei I, Li Y, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. *Endocr Relat Cancer* 2018;26:131–46.
- [21] Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. *Asian J Androl* 2014;16:378–86.
- [22] Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. *Prostate* 2015;75:242–54.
- [23] Yin Y, Li R, Xu K, et al. Androgen receptor variants mediate DNA repair after prostate cancer irradiation. *Cancer Res* 2017;77:4745–54.
- [24] Juvekar A, Hu H, Yadegarynia S, et al. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. *Proc Natl Acad Sci U S A* 2016;113:E4338–47.
- [25] Ta HQ, Gioeli D. The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. *Endocr Relat Cancer* 2014;21:R395–407.
- [26] Chakraborty G, Armenia J, Mazzu YZ, et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. *Clin Cancer Res* 2020;26:2047–64.
- [27] Stuparu AD, Capri JR, Meyer C, et al. Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer. *J Nucl Med*. In press. <https://doi.org/10.2967/jnumed.120.256263>.
- [28] Kratochwil C, Giesel FL, Heussel CP, et al. Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes. *J Nucl Med* 2020;61:683–8.
- [29] Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. *Nature* 2001;410:842–7.
- [30] Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. *J Natl Cancer Inst* 1998;90:978–85.
- [31] Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. *Prostate* 2010;70:305–16.
- [32] Yao V, Bacich DJ. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. *Prostate* 2006;66:867–75.
- [33] Affronti HC, Rowsam AM, Pellerite AJ, et al. Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. *Nat Commun* 2020;11:52.
- [34] Affronti HC, Long MD, Rosario SR, et al. Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model. *Oncotarget* 2017;8:103758–7.
- [35] Zacharias NM, McCullough C, Shanmugavelandy S, et al. Metabolic differences in glutamine utilization lead to metabolic vulnerabilities in prostate cancer. *Sci Rep* 2017;7:16159.
- [36] Wang Q, Hardie RA, Hoy AJ, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. *J Pathol* 2015;236:278–89.
- [37] Nguyen T, Kirsch BJ, Asaka R, et al. Uncovering the role of N-acetyl-aspartyl-glutamate as a glutamate reservoir in cancer. *Cell Rep* 2019;27, 491–501.e6.
- [38] Conway RE, Joiner K, Patterson A, et al. Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. *Angiogenesis* 2013;16:847–60.
- [39] Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. *Urol Res* 2005;33:44–50.
- [40] Wilson SR, Gallagher S, Warpeha K, Hawthorne SJ. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. *Prostate* 2004;60:168–74.
- [41] Conway RE, Rojas C, Alt J, et al. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. *Angiogenesis* 2016;19:487–500.
- [42] Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The metabolic phenotype of prostate cancer. *Front Oncol* 2017;7:131.
- [43] Koochekpour S, Majumdar S, Azabdaftari G, et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. *Clin Cancer Res* 2012;18:5888–901.
- [44] Banerjee SR, Pullambhatla M, Foss CA, et al. ^{64}Cu -labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. *J Med Chem* 2014;57:2657–69.
- [45] Violet J, Sandhu S, Iravani A, et al. Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of lutetium-177 (^{177}Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. *J Nucl Med* 2020;61:857–65.
- [46] Hofman MS, Emmett L, Violet J, et al. TheraP: a randomized phase 2 trial of ^{177}Lu -PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). *BJU Int* 2019;124(Suppl 1):5–13.
- [47] Ruigrok EAM, van Weerden WM, Nonnekens J, de Jong M. The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research. *Pharmaceutics* 2019;11:560.
- [48] Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. α -Emitters for radiotherapy: from basic radiochemistry to clinical studies—part 1. *J Nucl Med* 2018;59:878–84.
- [49] Hofman MS, Violet J, Hicks RJ, et al. ^{177}Lu -PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. *Lancet Oncol* 2018;19:825–33.
- [50] Hofman MS, Emmett L, Sandhu S, et al. ^{177}Lu -PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. *Lancet* 2021;397:797–804.
- [51] Morris MJ, de Bono JS, Chi KN, et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). In: Proceedings of the ASCO 2021 Annual Meeting. <https://meetinglibrary.asco.org/record/196661/abstract>.
- [52] Baum RP, Kulkarni HR, Schuchardt C, et al. ^{177}Lu -labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. *J Nucl Med* 2016;57:1006–13.
- [53] Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. *Semin Oncol* 2003;30:667–76.

784 [54] Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith
785 SJ, Bander NH. Phase I trial of yttrium-90–labeled anti–prostate-
786 specific membrane antigen monoclonal antibody J591 for andro-
787 gen-independent prostate cancer. *J Clin Oncol* 2004;22:2522–31.

788 [55] Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula
789 S, Goldsmith SJ. Phase I trial of ¹⁷⁷lutetium-labeled J591, a mono-
790 clonal antibody to prostate-specific membrane antigen, in patients
791 with androgen-independent prostate cancer. *J Clin Oncol*
792 2005;23:4591–601.

793 [56] Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-
794 177-labeled anti-prostate-specific membrane antigen monoclonal
795 antibody J591 for metastatic castration-resistant prostate cancer.
796 *Clin Cancer Res* 2013;19:5182–91.

797 [57] Tagawa ST, Vallabhajosula S, Christos PJ, et al. Phase 1/2 study of
798 fractionated dose lutetium-177-labeled anti-prostate-specific
799 membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for met-
800 astatic castration-resistant prostate cancer. *Cancer* 2019;125:2561–
801 9.

802 [58] Vallabhajosula S, Goldsmith SJ, Hamacher KA, et al. Prediction of
803 myelotoxicity based on bone marrow radiation-absorbed dose:
804 radioimmunotherapy studies using ⁹⁰Y- and ¹⁷⁷Lu-labeled J591
805 antibodies specific for prostate-specific membrane antigen. *J Nucl*
806 *Med* 2005;46:850–8.

807 [59] Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus
808 DM, Bander NH. Radioimmunotherapy of prostate cancer using ⁹⁰Y-
809 and ¹⁷⁷Lu-labeled J591 monoclonal antibodies: effect of multiple
810 treatments on myelotoxicity. *Clin Cancer Res* 2005;11, 7195s–200s.

811 [60] Niaz MJ, Batra JS, Walsh RD, et al. Pilot study of hyperfractionated
812 dosing of lutetium-177-labeled antiprostate-specific membrane
813 antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic cas-
814 tration-resistant prostate cancer. *Oncologist* 2020;25(477):e895.

815 [61] Tagawa ST, Osborne J, Niaz MJ, et al. Dose-escalation results of a
816 phase I study of ²²⁵Ac-J591 for progressive metastatic castration
817 resistant prostate cancer (mCRPC). *J Clin Oncol* 2020;38
818 (6 Suppl):114.

819 [62] Hammer S, Hagemann UB, Zitzmann-Kolbe S, et al. Preclinical
820 efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC),
821 a targeted alpha therapy for prostate cancer. *Clin Cancer Res*
822 2020;26:1985–96.

823 [63] Zacherl MJ, Gildehaus FJ, Mittlmeier L, et al. First clinical results for
824 PSMA-targeted α-therapy using ²²⁵Ac-PSMA-I&T in advanced-
825 mCRPC patients. *J Nucl Med* 2021;62:669–74.

826 [64] Kratochwil C, Haberkorn U, Giesel FL. ²²⁵Ac-PSMA-617 for therapy
827 of prostate cancer. *Semin Nucl Med* 2020;50:133–40.

828 [65] Satheke M, Bruchertseifer F, Knoesen O, et al. ²²⁵Ac-PSMA-617 in
829 chemotherapy-naïve patients with advanced prostate cancer: a
830 pilot study. *Eur J Nucl Med Mol Imaging* 2019;46:129–38.

831 [66] Leconet W, Liu H, Guo M, et al. Anti-PSMA/CD3 bispecific antibody
832 delivery and antitumor activity using a polymeric depot formula-
833 tion. *Mol Cancer Ther* 2018;17:1927–40.

834 [67] Friedrich M, Raum T, Lutterbuese R, et al. Regression of human
835 prostate cancer xenografts in mice by AMG 212/BAY2010112, a
836 novel PSMA/CD3-bispecific BiTE antibody cross-reactive with
837 non-human primate antigens. *Mol Cancer Therapeut*
838 2012;11:2664–73.

839 [68] Hummel H-D, Kufer P, Grüllich C, et al. Phase 1 study of pasotux-
840 izumab (BAY 2010112), a PSMA-targeting bispecific T cell engager
841 (BiTE) immunotherapy for metastatic castration-resistant prostate
842 cancer (mCRPC). *J Clin Oncol* 2019;37(15 Suppl):5034.

843 [69] Lemon B, Aaron W, Austin R, et al. Abstract 1773: HPN424, a half-life
844 extended, PSMA/CD3-specific TriTAC for the treatment of meta-
845 static prostate cancer. *Cancer Res* 2018;78(13 Suppl):1773.

846 [70] Deegen P, Thomas O, Nolan-Stevaux O, et al. The PSMA-targeting
847 half-life extended BiTE® therapy AMG 160 has potent antitumor
848 activity in preclinical models of metastatic castration-resistant
849 prostate cancer. *Clin Cancer Res* 2021;27:2928–37.

850 [71] Tran B, Horvath L, Dorff TB, et al. Phase I study of AMG 160, a half-life
851 extended bispecific T-cell engager (HLE BiTE) immune therapy
852 targeting prostate-specific membrane antigen (PSMA), in patients
853 with metastatic castration-resistant prostate cancer (mCRPC). *J Clin*
854 *Oncol* 2020;38(15 Suppl):TPS261.

855 [72] Hummel H-D, Kufer P, Grüllich C, et al. Pasotuxizumab, a
856 BiTE® immune therapy for castration-resistant prostate cancer:
857 phase I, dose-escalation study findings. *Immunotherapy*
858 2021;13:125–41.

859 [73] Petrylak DP, Kantoff P, Vogelzang NJ, et al. Phase 1 study of PSMA
860 ADC, an antibody-drug conjugate targeting prostate-specific mem-
861 brane antigen, in chemotherapy-refractory prostate cancer. *Prostate*
862 2019;79:604–13.

863 [74] Petrylak DP, Vogelzang NJ, Chatta GS, et al. A phase 2 study of
864 prostate specific membrane antigen antibody drug conjugate
865 (PSMA ADC) in patients (pts) with progressive metastatic castra-
866 tion-resistant prostate cancer (mCRPC) following abiraterone and/
867 or enzalutamide (abi/enz). *J Clin Oncol* 2015;33(7 Suppl):144.

868 [75] Petrylak DP, Smith DC, Appleman LJ, et al. A phase 2 trial of prostate-
869 specific membrane antigen antibody drug conjugate (PSMA ADC) in
870 taxane-refractory metastatic castration-resistant prostate cancer
871 (mCRPC). *J Clin Oncol* 2014;32(15 Suppl):5023.

872 [76] Milowsky MI, Galsky MD, Morris MJ, et al. Phase 1/2 multiple
873 ascending dose trial of the prostate-specific membrane anti-
874 gen-targeted antibody drug conjugate MLN2704 in metastatic
875 castration-resistant prostate cancer. *Urol Oncol* 2016;34, 530.
876 e15–21.

877 [77] Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the
878 prostate-specific membrane antigen–directed immunoconjugate
879 MLN2704 in patients with progressive metastatic castration-resis-
880 tant prostate cancer. *J Clin Oncol* 2008;26:2147–54.

881 [78] Hofman MS, Emmett L, Sandhu SK, et al. TheraP: a randomised
882 phase II trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) theranostic versus
883 cabazitaxel in metastatic castration resistant prostate cancer
884 (mCRPC) progressing after docetaxel: initial results (ANZUP pro-
885 tocol 1603). *J Clin Oncol* 2020;38(15 Suppl), 5500–5500.

886 [79] Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes
887 G. Heterogeneity of prostate-specific membrane antigen (PSMA)
888 expression in prostate carcinoma with distant metastasis. *Pathol*
889 *Oncol Res* 2009;15:167–72.

890 [80] Harsini S, Sapruff H, Alden T, Mohammadi B, Wilson D, Benard F.
891 The effects of monosodium glutamate on PSMA radiotracer uptake
892 in men with recurrent prostate cancer: a prospective, randomized,
893 double-blind, placebo-controlled intraindividual imaging study. *J*
894 *Nucl Med* 2021;62:81–7.

895 [81] Armstrong WR, Gafita A, Zhu S, et al. The impact of monosodium
896 glutamate on ⁶⁸Ga-PSMA-11 biodistribution in men with prostate
897 cancer: a prospective randomized, controlled, imaging study. *J Nucl*
898 *Med*. In press. <https://doi.org/10.2967/jnumed.120.257931>.

899 [82] Ferraro DA, Rüschoff JH, Muehlematter UJ, et al. Immunohisto-
900 chemical PSMA expression patterns of primary prostate cancer
901 tissue are associated with the detection rate of biochemical recur-
902 rence with ⁶⁸Ga-PSMA-11-PET. *Theranostics* 2020;10:6082–94.

903 [83] Wright Jr GL, Grob BM, Haley C, et al. Upregulation of prostate-
904 specific membrane antigen after androgen-deprivation therapy.
905 *Urology* 1996;48:326–34.

906 [84] Hope TA, Truillet C, Ehman EC, et al. ⁶⁸Ga-PSMA-11 PET imaging of
907 response to androgen receptor inhibition: first human experience. *J*
908 *Nucl Med* 2017;58:81–4.

909 [85] Luckerath K, Wei L, Fendler WP, et al. Preclinical evaluation of PSMA
910 expression in response to androgen receptor blockade for thera-
911 nostics in prostate cancer. *EJNMMI Res* 2018;8:96.

899 [86] Sekhar KR, Wang J, Freeman ML, Kirschner AN. Radiosensitization of 921
 900 by enzalutamide for human prostate cancer is mediated through 922
 901 the DNA damage repair pathway. *PLoS One* 2019;14:e0214670. 923
 902 [87] Kranzbühler B, Salemi S, Umbricht CA, et al. Pharmacological 924
 903 upregulation of prostate-specific membrane antigen (PSMA) 925
 904 expression in prostate cancer cells. *Prostate* 2018;78:758-65. 926
 905 [88] Batra JS, Niaz MJ, Whang YE, et al. Phase I trial of docetaxel plus 927
 906 lutetium-177-labeled anti-prostate-specific membrane antigen 928
 907 monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration- 929
 908 resistant prostate cancer. *Urol Oncol* 2020;38, 848.e9-16. 930
 909 [89] Yin Y, Li R, Xu KL, et al. Androgen receptor variants mediate DNA 931
 910 repair after prostate cancer irradiation. *Cancer Res* 2017;77:4745- 932
 911 54. 933
 912 [90] Spratt DE, Evans MJ, Davis BJ, et al. Androgen receptor upregulation 934
 913 mediates radioresistance after ionizing radiation. *Cancer Res* 935
 914 2015;75:4688-96. 936
 915 [91] Mole RH. Whole body irradiation; radiobiology or medicine? *Br J* 937
 916 *Radiol* 1953;26:234-41. 938
 917 [92] Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. 939
 918 Using immunotherapy to boost the abscopal effect. *Nat Rev Cancer* 940
 919 2018;18:313-22. 941
 920 [93] Bakhom SF, Ngo B, Laughney AM, et al. Chromosomal instability
 drives metastasis through a cytosolic DNA response. *Nature*
 2018;553:467-72.

[94] Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of
 cytosolic DNA sensing and signaling. *Mol Cell* 2014;54:289-96.

[95] Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics
 with immunotherapy: more haste, less speed. *Br J Cancer*
 2018;118:312-24.

[96] Czernin J, Current K, Mona CE, et al. Immune-checkpoint blockade
 enhances ²²⁵Ac-PSMA617 efficacy in a mouse model of prostate
 cancer. *J Nucl Med* 2021;62:228-31.

[97] Tagawa ST, Batra J, Vallabhajosula S, et al. Final results of 2-dose
 fractionation of ¹⁷⁷Lu-J591 for progressive metastatic castration-
 resistant prostate cancer (mCRPC). *J Clin Oncol* 2016;34
 (15 Suppl):5022.

[98] Bendell JC, Fong L, Stein MN, et al. First-in-human phase I study of
 HPN424, a tri-specific half-life extended PSMA-targeting T-cell
 engager in patients with metastatic castration-resistant prostate
 cancer (mCRPC). *J Clin Oncol* 2020;38(15 Suppl):5552.

[99] VISION Trial Investigators. Morris M, de Bono JS, Chi KN, et al. Phase
 III study of lutetium-177-PSMA-617 in patients with metastatic
 castration-resistant prostate cancer (VISION). *J Clin Oncol*
 2021;39(15 Suppl). http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.LBA4.